LEADER 04588nam 22004815 450 001 9910298433003321 005 20200705064905.0 010 $a3-319-89689-X 024 7 $a10.1007/978-3-319-89689-2 035 $a(CKB)4100000004835966 035 $a(MiAaPQ)EBC5433807 035 $a(DE-He213)978-3-319-89689-2 035 $a(PPN)229493858 035 $a(EXLCZ)994100000004835966 100 $a20180618d2018 u| 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aRNA Metabolism in Neurodegenerative Diseases /$fedited by Rita Sattler, Christopher J. Donnelly 205 $a1st ed. 2018. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2018. 215 $a1 online resource (321 pages) 225 1 $aAdvances in Neurobiology,$x2190-5215 ;$v20 311 $a3-319-89688-1 327 $aRNA Metabolism in Neurodegenerative Diseases -- Mechanism of Splicing Regulation of Spinal Muscular Atrophy Genes -- RNA Editing Deficiency in Neurodegeneration -- RNA Nucleocytoplasmic Transport Defects in Neurodegenerative Diseases -- RNA Degradation in Neurodegenerative Disease -- RNP Assembly Defects in Spinal Muscular Atrophy -- Stress Granules and ALS: A Case of Causation or Correlation? -- Deregulation of RNA Metabolism in Microsatellite Expansion Diseases -- Mechanisms Associated with TDP-43 Neurotoxicity in ALS/FTLD -- Senataxin, a Novel Helicase at the Interface of RNA Transcriptome Regulation and Neurobiology: From Normal Function to Pathological Roles in Motor Neuron Disease and Cerebellar Degeneration -- Lost in Translation ? Evidence for Protein Synthesis Deficits in ALS/FTD and Related Neurodegenerative Diseases. 330 $aIt has become evident over the last years that abnormalities in RNA processing play a fundamental part in the pathogenesis of neurodegenerative diseases. Cellular viability depends on proper regulation of RNA metabolism and subsequent protein synthesis, which requires the interplay of many processes including transcription, pre?mRNA splicing, mRNA editing as well as mRNA stability, transport and translation. Dysfunction in any of these processes, often caused by mutations in the coding and non?coding RNAs, can be very destructive to the cellular environment and consequently impair neural viability. The result of this RNA toxicity can lead to a toxic gain of function or a loss of function, depending on the nature of the mutation. For example, in repeat expansion disorders, such as the newly discovered hexanucleotide repeat expansion in theC9orf72 gene found in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), a toxic gain of function leads to the formation of RNA foci and the sequestration of RNA binding proteins (RBPs). This in return leads to a loss of function of those RBPs, which is hypothesized to play a significant part in the disease progression of ALS and FTD. Other toxicities arising from repeat expansions are the formation of RNA foci, bi?directional transcription and production of repeat associated non?ATG (RAN) translation products. This book will touch upon most of these disease mechanisms triggered by aberrant RNA metabolism and will therefore provide a broad perspective of the role of RNA processing and its dysfunction in a variety of neurodegenerative disorders, including ALS, FTD, Alzheimer?s disease, Huntington?s disease, spinal muscular atrophy, myotonic dystrophy and ataxias. The proposed authors are leading scientists in the field and are expected to not only discuss their own work, but to be inclusive of historic as well as late breaking discoveries. The compiled chapters will therefore provide a unique collection of novel studies and hypotheses aimed to describe the consequences of altered RNA processing events and its newest molecular players and pathways. 410 0$aAdvances in Neurobiology,$x2190-5215 ;$v20 606 $aNeurosciences 606 $aNeurosciences$3https://scigraph.springernature.com/ontologies/product-market-codes/B18006 615 0$aNeurosciences. 615 14$aNeurosciences. 676 $a616.8047 702 $aSattler$b Rita$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aDonnelly$b Christopher J$4edt$4http://id.loc.gov/vocabulary/relators/edt 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910298433003321 996 $aRNA Metabolism in Neurodegenerative Diseases$92536238 997 $aUNINA LEADER 00855nam 2200253 450 001 996667172603316 005 20250715143809.0 100 $a20250715d1999----km y0itay5003 ba 101 0 $aita 102 $aIT 105 $ay 00 y 200 1 $aInosservanze dell'impresa e tutela contrattuale dell'assicurato nelle assicurazioni private contro i danni$fPaoloefisio Corrias 210 $aCagliari$cEttore Gasperini Editore$d1999 215 $a130 p.$d24 cm 606 0 $aAssicurazioni private$2BNCF 676 $a346.45086 700 1$aCORRIAS,$bPaoloefisio$0279457 801 0$aIT$bcba$gREICAT 912 $a996667172603316 951 $aXVI.7.A. 514$bFBUO$cXVI.7.A. 959 $aBK 969 $aFBUO 996 $aInosservanze dell'impresa e tutela contrattuale dell'assicurato nelle assicurazioni private contro i danni$94404993 997 $aUNISA